|
Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study. |
|
|
Leadership - Capio BioSciences |
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Sanofi; Vizuri |
Speakers' Bureau - Bayer; Exelixis; Sanofi |
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen Biotech; Merck; Myovant Sciences |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Genomic Health; Janssen Biotech; MDxHealth; Merck; Myovant Sciences; Precision Biopsy; TesoRX Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Employment - Chesapeake Urology |
Stock and Other Ownership Interests - Myovant Sciences; Novartis; Nymox; Veru |
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences |
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer |
Research Funding - Advantagene (Inst); Advaxis (Inst); Bayer (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); Neotract (Inst); Nymox (Inst); OncoCellMDx (Inst); OncoCellMDx (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; Myovant Sciences; Taiho Pharmaceutical |
Speakers' Bureau - Myovant Sciences; Pfizer |
Research Funding - Astellas Pharma (Inst); Nippon Kayaku (Inst); Takeda (Inst); Yakult Honsha (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Myovant Sciences |
|
|
Employment - Myovant Sciences |
|
|
Employment - Myovant Sciences |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda |
Speakers' Bureau - Amgen; Janssen |
Research Funding - Ferring (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |